For research use only. Not for therapeutic Use.
Lumefantrine（Cat No.:I004976）is an antimalarial drug that is commonly used in combination with Artemether. Together, they form a combination therapy known as artemether-lumefantrine (AL). This combination is considered a first- and second-line treatment for malaria, particularly caused by Plasmodium falciparum. Lumefantrine works by inhibiting the growth and reproduction of the malaria parasite, while artemether acts to rapidly reduce the parasite load. The combination therapy is effective against both uncomplicated and severe malaria cases and has become a widely used treatment option in many malaria-endemic regions.
| Catalog Number | I004976 |
| CAS Number | 82186-77-4 |
| Synonyms | Benflumetol;CPG-56695 |
| Molecular Formula | C30H32Cl3NO |
| Purity | ≥95% |
| Solubility | 10 mM in DMSO |
| Storage | -20°C |
| IUPAC Name | 2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-[(4-chlorophenyl)methylidene]fluoren-4-yl]ethanol |
| InChI | InChI=1S/C30H32Cl3NO/c1-3-5-13-34(14-6-4-2)19-29(35)28-18-23(33)17-27-25(15-20-7-9-21(31)10-8-20)26-16-22(32)11-12-24(26)30(27)28/h7-12,15-18,29,35H,3-6,13-14,19H2,1-2H3/b25-15- |
| InChIKey | DYLGFOYVTXJFJP-MYYYXRDXSA-N |
| SMILES | CCCCN(CCCC)CC(C1=CC(=CC\2=C1C3=C(/C2=C/C4=CC=C(C=C4)Cl)C=C(C=C3)Cl)Cl)O |
| Reference | </br>1:Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial. Abreha T, Hwang J, Thriemer K, Tadesse Y, Girma S, Melaku Z, Assef A, Kassa M, Chatfield MD, Landman KZ, Chenet SM, Lucchi NW, Udhayakumar V, Zhou Z, Shi YP, Kachur SP, Jima D, Kebede A, Solomon H, Mekasha A, Alemayehu BH, Malone JL, Dissanayake G, Teka H, Auburn S, von Seidlein L, Price RN.PLoS Med. 2017 May 16;14(5):e1002299. doi: 10.1371/journal.pmed.1002299. eCollection 2017 May. PMID: 28510573 Free Article</br>2:Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine Exert Inverse Selective Pressure on <i>Plasmodium Falciparum</i> Drug Sensitivity-Associated Haplotypes in Uganda. Taylor AR, Flegg JA, Holmes CC, Guérin PJ, Sibley CH, Conrad MD, Dorsey G, Rosenthal PJ.Open Forum Infect Dis. 2016 Oct 25;4(1):ofw229. doi: 10.1093/ofid/ofw229. eCollection 2017 Winter. PMID: 28480232 Free PMC Article</br>3:Baseline in vivo, ex vivo and molecular responses of Plasmodium falciparum to artemether and lumefantrine in three endemic zones for malaria in Colombia. Aponte S, Guerra ÁP, Álvarez-Larrotta C, Bernal SD, Restrepo C, González C, Yasnot MF, Knudson-Ospina A.Trans R Soc Trop Med Hyg. 2017 Feb 1;111(2):71-80. doi: 10.1093/trstmh/trx021. PMID: 28460112 </br>4:Therapeutic efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in a high-transmission area in northwest Ethiopia. Teklemariam M, Assefa A, Kassa M, Mohammed H, Mamo H.PLoS One. 2017 Apr 26;12(4):e0176004. doi: 10.1371/journal.pone.0176004. eCollection 2017. PMID: 28445503 Free PMC Article</br>5:Genomic Characterization of Recrudescent Plasmodium malariae after Treatment with Artemether/Lumefantrine. Rutledge GG, Marr I, Huang GKL, Auburn S, Marfurt J, Sanders M, White NJ, Berriman M, Newbold CI, Anstey NM, Otto TD, Price RN.Emerg Infect Dis. 2017 Aug 15;23(8). doi: 10.3201/eid2308.161582. [Epub ahead of print] PMID: 28430103 Free Article</br>6:The Relative Effects of Artemether-lumefantrine and Non-artemisinin Antimalarials on Gametocyte Carriage and Transmission of Plasmodium falciparum: A Systematic Review and Meta-analysis. Ippolito MM, Johnson J, Mullin C, Mallow C, Morgan N, Wallender E, Li T, Rosenthal PJ.Clin Infect Dis. 2017 Apr 11. doi: 10.1093/cid/cix336. [Epub ahead of print] PMID: 28402391 </br>7:Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria at sentinel sites in Mozambique, 2015. Salvador C, Rafael B, Matsinhe F, Candrinho B, Muthemba R, De Carvalho E, Naueia E, Sacarlal J, Namboze J, Tiago A, Warsame M, Enosse S.Acta Trop. 2017 Apr 1;171:146-150. doi: 10.1016/j.actatropica.2017.03.032. [Epub ahead of print] PMID: 28373036 </br>8:Artemether-Lumefantrine Treatment Failure in Nonimmune European Travelers With Plasmodium falciparum Malaria: Do We Need to Reconsider Dosing in Patients From Nonendemic Regions? Neumayr A, Paris DH, Genton B, Hatz C.Clin Infect Dis. 2017 May 15;64(10):1466-1467. doi: 10.1093/cid/cix262. No abstract available. PMID: 28369315 </br>9:In vivo efficacy of artemether-lumefantrine against uncomplicated <i>Plasmodium falciparum</i> malaria in Dembia District, northwest Ethiopia. Deressa T, Seid ME, Birhan W, Aleka Y, Tebeje BM.Ther Clin Risk Manag. 2017 Feb 16;13:201-206. doi: 10.2147/TCRM.S127571. eCollection 2017. PMID: 28243110 Free PMC Article</br>10:Development of Delayed Hemolytic Anemia After Treatment with Oral Artemether-Lumefantrine in Two Patients with Severe Falciparum Malaria. Tsuchido Y, Nakamura-Uchiyama F, Toyoda K, Iwagami M, Tochitani K, Shinohara K, Hishiya N, Ogawa T, Uno K, Kasahara K, Ouji Y, Kano S, Mikasa K, Shimizu T, Yoshikawa M, Maruyama H.Am J Trop Med Hyg. 2017 May;96(5):1185-1189. doi: 10.4269/ajtmh.16-0460. Epub 2017 Feb 13. PMID: 28193740 |
